Trial Profile
Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Dec 2017
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms ESDAC
- 05 Dec 2017 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Dec 2015).
- 29 Dec 2015 New trial record